Ascendis Pharma A/S (ASND)
NASDAQ:ASND
Earnings Data
Report Date
May 27, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.24Last Year’s EPS
-1.85Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call was constructive and growth-focused: management reported strong commercial execution (notably Yorvipath and Skytrofa), meaningful pipeline and regulatory progress (including imminent PDUFA for TransCon CNP and compelling combination data), and a strengthened cash position with an ambitious operating cash flow outlook for 2026. Key headwinds include high operating expenses (which slightly exceeded 2025 revenue), a substantial noncash finance remeasurement loss, currency-driven revenue headwinds, and remaining access / penetration and competitive uncertainties. Taken together the positives around revenue momentum, pipeline advancement, partnerships, and a stronger financial base outweigh the near-term financial and market-access challenges.Company Guidance
Yorvipath revenue surge and broadening access
Q4 2025 Yorvipath revenue of €187,000,000, up from €140,000,000 in Q3 2025 (+33.6% quarter-over-quarter); full-year 2025 revenue €477,000,000. More than 5,300 US patients prescribed by ~2,400 prescribers; insurance approval rate ~70% with majority approved within eight weeks. Yorvipath available commercially or via named-patient programs in >30 countries, with full commercial reimbursement in multiple markets and 10 additional full commercial launches expected in 2026.
Skytrofa solid commercial performance
Skytrofa Q4 2025 revenue €53,000,000 and full-year 2025 revenue €206,000,000; achieved ~7% overall US market share. Launched Phase III basket trial to expand indications (ISS, SHOX deficiency, Turner syndrome, SGA) representing up to ~50% of the growth hormone market.
Company revenue, cash and operating cash flow
Total Q4 2025 revenue €248,000,000 (including €7,000,000 collaboration revenue); total 2025 revenue €720,000,000. Year-end cash and cash equivalents €616,000,000, up from €560,000,000 (+~10%). Q4 operating cash flow €73,000,000.
Pipeline and regulatory momentum
TransCon CNP NDA under FDA review with a PDUFA date of Feb 28, 2026; Phase II 52-week combination data showed 3–4x linear growth improvement versus monotherapy and meaningful benefits in body proportionality and arm span without compromising safety. End-of-Phase-2 and scientific advice meetings with FDA/EU were positive and Phase III alignment achieved. Progress on once-weekly TransCon PTH preclinical PK/PD supporting a weekly profile comparable to daily therapy; Phase III/label-expansion programs moving forward. Strategic partnerships (e.g., Novo Nordisk for once-monthly semaglutide) are advancing toward the clinic.
Ambitious financial outlook
Management expects operating cash flow of ~€500,000,000 in 2026 and aspires to at least €5,000,000,000 in annual product revenue by 2030, reflecting strong confidence in the commercial rollout and pipeline value.
ASND Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ASND Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 11, 2026 | $221.49 | $218.10 | -1.53% |
Nov 12, 2025 | $199.22 | $206.45 | +3.63% |
Aug 07, 2025 | $190.35 | $191.49 | +0.60% |
May 01, 2025 | $167.47 | $172.06 | +2.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ascendis Pharma A/S (ASND) report earnings?
Ascendis Pharma A/S (ASND) is schdueled to report earning on May 27, 2026, TBA (Confirmed).
What is Ascendis Pharma A/S (ASND) earnings time?
Ascendis Pharma A/S (ASND) earnings time is at May 27, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ASND EPS forecast?
ASND EPS forecast for the fiscal quarter 2026 (Q1) is 0.24.